Skip to main content

Advertisement

Log in

The protein kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer: meta-analysis of randomized controlled trials

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Background

The application of newer signaling pathway-targeted agents has become an important addition to chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). In this study, we evaluated the efficacy and toxicities of PKC inhibitors combined with chemotherapy versus chemotherapy alone for patients with advanced NSCLC systematically.

Patients and materials

Literature retrieval, trials selection and assessment, data collection, and statistic analysis were performed according to the Cochrane Handbook 5.1.0. The outcome measures were tumor response rate, disease control rate, progression-free survival (PFS), overall survival (OS), and adverse effects.

Results

Five randomized controlled trials, comprising totally 1,005 patients, were included in this study. Meta-analysis showed significantly decreased response rate (RR 0.79; 95 % CI 0.64–0.99) and disease control rate (RR 0.90; 95 % CI 0.82–0.99) in PKC inhibitors-chemotherapy groups versus chemotherapy groups. There was no significant difference between the two treatment groups regarding progression-free survival (PFS, HR 1.05; 95 % CI 0.91–1.22) and overall survival (OS, HR 1.00; 95 % CI 0.86–1.16). The risk of grade 3/4 neutropenia, leucopenia, and thrombosis/embolism increased significantly in PKC inhibitors combination groups as compared with chemotherapy alone groups.

Conclusion

The use of PKC inhibitors in addition to chemotherapy was not a valid alternative for patients with advanced NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.

    Article  PubMed  Google Scholar 

  2. D’Addario G, Fruh M, Reck M, Baumann P, Klepetko W, Felip E, et al. Metastatic non-small-cell lung cancer. ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii56–vii64.

  3. Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol. 2009;27(20):3277–83.

    Article  PubMed  Google Scholar 

  4. Clark AS, West KA, Blumberg PM, Dennis PA. Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. Cancer Res. 2003;63(4):780–6.

    CAS  PubMed  Google Scholar 

  5. Martiny-Baron G, Fabbro D. Classical PKC isoforms in cancer. Pharmacol Res. 2007;55(6):477–86.

    Article  CAS  PubMed  Google Scholar 

  6. Winegarden JD, Mauer AM, Gajewski TF, Hoffman PC, Krauss S, Rudin CM, et al. A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer. 2003;39(2):191–6.

    Article  PubMed  Google Scholar 

  7. Edelman MJ, Bauer KS Jr, Wu S, Smith R, Bisacia S, Dancey J. Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors. Clin Cancer Res. 2007;13(9):2667–74.

    Article  CAS  PubMed  Google Scholar 

  8. Mack PC, Gandara DR, Lau AH, Lara PN Jr, Edelman MJ, Gumerlock PH. Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma. Cancer Chemother Pharmacol. 2003;51(4):337–48.

    CAS  PubMed  Google Scholar 

  9. Monnerat C, Henriksson R, Le Chevalier T, Novello S, Berthaud P, Faivre S, et al. Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. Ann Oncol. 2004;15(2):316–23.

    Article  CAS  PubMed  Google Scholar 

  10. Vansteenkiste J, Canon JL, Riska H, Pirker R, Peterson P, John W, et al. Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer. Invest New Drugs. 2005;23(3):263–9.

    Article  CAS  PubMed  Google Scholar 

  11. Socinski MA, Raju RN, Stinchcombe T, Kocs DM, Couch LS, Barrera D, et al. Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol. 2010;5(12):1963–9.

    Article  PubMed  Google Scholar 

  12. Mansfield AS, Fields AP, Jatoi A, Qi Y, Adjei AA, Erlichman C, et al. Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer. Anticancer Drugs. 2013;24(10):1079–83.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Nakajima E, Helfrich B, Chan D, Zhang Z, Hirsch FR, Chen V, et al. Enzastaurin, a protein kinase C-beta-selective inhibitor, inhibits the growth of SCLC and NSCLC cell lines. J Clin Oncol. 2006;24:612s (abstract 13138).

  14. Giovannetti E, Honeywell R, Hanauske AR, Tekle C, Kuenen B, Sigmond J, et al. Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC). Curr Drug Targets. 2010;11(1):12–28.

    Article  CAS  PubMed  Google Scholar 

  15. Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol. 2006;24:4092–9.

    Article  CAS  PubMed  Google Scholar 

  16. Villalona-Calero MA, Ritch P, Figueroa JA, Otterson GA, Belt R, Dow E, et al. A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2004;10:6086–93.

    Article  CAS  PubMed  Google Scholar 

  17. Casey EM, Harb W, Bradford D, Bufill J, Nattam S, Patel J, et al. Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplat in, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116. J Thorac Oncol. 2010;5(11):1815–20.

    Article  PubMed  Google Scholar 

  18. Chiappori A, Bepler G, Barlesi F, Soria JC, Reck M, Bearz A, et al. Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(3):369–75.

    Article  PubMed  Google Scholar 

  19. Paz-Ares L, Douillard JY, Koralewski P, Manegold C, Smit EF, Reyes JM, et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2006;24(9):1428–34.

    Article  CAS  PubMed  Google Scholar 

  20. Lee SH, Chen T, Zhou J, Hofmann J, Bepler G. Protein kinase C-beta gene variants, pathway activation, and enzastaurin activity in lung cancer. Clin Lung Cancer. 2010;11:169–75.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Ritch P, Rudin CM, Bitran JD, Edelman MJ, Makalinao A, Irwin D, et al. Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2006;52(2):173–80.

    Article  PubMed  Google Scholar 

  22. Körner A, Mudduluru G, Manegold C, Allgayer H. Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules. Br J Cancer. 2010;103(6):802–11.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Kuo WL, Liu J, Mauceri H, Vokes EE, Weichselbaum R, Rosner MR, et al. Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context. Mol Cancer Ther. 2010;9(10):2814–24.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Regala RP, Thompson EA, Fields AP. Atypical protein kinase C iota expression and aurothiomalate sensitivity in human lung cancer cells. Cancer Res. 2008;68(14):5888–95.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Justilien V, Walsh MP, Ali SA, Thompson EA, Murray NR, Fields AP. The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell. 2014;25(2):139–51.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Kim ES, Neubauer M, Cohn A, Schwartzberg L, Garbo L, Caton J, et al. Docetaxed or pemetrexed with of without cetuximab in recurrent or progressive non-small cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Lancet Oncol. 2013;14(13):1326–36.

    Article  CAS  PubMed  Google Scholar 

  27. Dy GK, Mandrekar SJ, Nelson GD, Meyers JP, Adjei AA, Ross HJ, et al. A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non–small-cell lung cancer, north central cancer treatment group study N0528. J Thorac Oncol. 2013;8(1):79–88.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Harper MT, Poole AW. Diverse functions of protein kinase C isoforms in platelet activation and thrombus formation. J Thromb Haemost. 2010;8(3):454–62.

    Article  CAS  PubMed  Google Scholar 

  29. Fisher MD, D’Orazio A. Phase II and III trials: comparison of four chemotherapy regimens in advanced non small-cell lung cancer (ECOG 1594). Clin Lung Cancer. 2000;2(1):21–2.

    Article  CAS  PubMed  Google Scholar 

  30. Gridelli C, de Marinis F, Pujol JL, Reck M, Ramlau R, Parente B, et al. Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2012;7(11):1713–21.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the Grants from Tianjin Medical University Science Foundation (No. 2012kyq16), Application Foundation and Front Technology Research Program of Tianjin (No. 13JCQNJC12500), High School Science and Technology Fund Planning Project of Tianjin (No. 20130112).

Conflict of interest

All authors declare no conflict of interest of this article.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to L. L. Zhang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, L.L., Cao, F.F., Wang, Y. et al. The protein kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer: meta-analysis of randomized controlled trials. Clin Transl Oncol 17, 371–377 (2015). https://doi.org/10.1007/s12094-014-1241-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-014-1241-3

Keywords

Navigation